{"nctId":"NCT02074982","briefTitle":"Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis","startDateStruct":{"date":"2014-02-26","type":"ACTUAL"},"conditions":["Chronic Plaque Type Psoriasis"],"count":676,"armGroups":[{"label":"AIN457 300 mg","type":"EXPERIMENTAL","interventionNames":["Drug: AIN457 300 mg"]},{"label":"Ustekinumab","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: ustekinumab 45/90 mg","Drug: placebo secukinumab"]}],"interventions":[{"name":"AIN457 300 mg","otherNames":["secukinumab"]},{"name":"ustekinumab 45/90 mg","otherNames":[]},{"name":"placebo secukinumab","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* patients with moderate to severe plaque type psoriasis for at least 6 months before randomization\n* patients eligible for systemic therapy with inadequately controlled psoriasis\n\nExclusion Criteria:\n\n* forms of sporiasis other than plaque type psoriasis\n* previous exposure to secukinumab, ustekinumab, or other biologic drugs targeting (IL)-17A or IL-17RA\n\nOther protocol-defined inclusion/exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Moderate to Severe Plaque Psoriasis Who Achieved Psoriasis Area and Severity Index (PASI) 90 at Week 16","description":"Psoriasis Area and Severity Index (PASI) is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).\n\nPASI 90 responders were defined as participants achieving ≥ 90% improvement at Week 16","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79.0","spread":null},{"groupId":"OG001","value":"57.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Speed of Onset Based on the Percentage of Participents Achieving PASI 75 at Week 4","description":"Psoriasis Area and Severity Index (PASI) is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).\n\nSpeed of Onset was based on percentage PASI 75 responders and were defined as participants achieving ≥ 75% improvement at Week 4","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49.7","spread":null},{"groupId":"OG001","value":"20.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Moderate to Severe Plaque Psoriasis Who Achieved Psoriasis Area and Severity Index (PASI) 90 at Week 52","description":"Psoriasis Area and Severity Index (PASI) is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).\n\nPASI 90 responders were defined as participants achieving ≥ 90% improvement at Week 52","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.9","spread":null},{"groupId":"OG001","value":"60.6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":41,"n":335},"commonTop":["NASOPHARYNGITIS","HEADACHE","UPPER RESPIRATORY TRACT INFECTION","ARTHRALGIA","BACK PAIN"]}}}